Diagnostic and therapeutic potential of transforming growth factor beta 1 in solid organ transplantation: recent research findings

S. Sharapchenko, A. Mamedova, O. Shevchenko
{"title":"Diagnostic and therapeutic potential of transforming growth factor beta 1 in solid organ transplantation: recent research findings","authors":"S. Sharapchenko, A. Mamedova, O. Shevchenko","doi":"10.15825/1995-1191-2023-2-148-157","DOIUrl":null,"url":null,"abstract":"Federation Clinical outcomes of solid organ transplantation depend on many factors. One of the main factors is the risk of post-transplant complications, which affect allograft and recipient survival. Multifactorial organ damage in post-transplant complications and the search for diagnostic and prognostic indicators of the condition have contributed to the study and selection of a wide range of proteomic and molecular genetic biomarkers, which have shown to be effective in solid organ transplantation. The use of biomarkers opens up additional possibilities for assessing the risk of complications and their early diagnosis. This potentially reduces the frequency of invasive diagnostic procedures. Transforming growth factor beta 1 (TGF-β1) regulates many biological processes, has anti-inflammatory and immunosuppressive effects, participates in immune response, and plays a key role in extracellular matrix (ECM) protein synthesis. ECM dysregulation leads to fibroblast hyperproliferation and increased collagen synthesis and, consequently, tissue fibrosis. The variability of the diagnostic and prognostic potential of TGF-β1 has been demonstrated in studies on recipients of various solid organs. The objective of this review is to analyze recent evidence on the role of TGF-β1 in the development of post-transplant complications and to assess its prospects as a marker of graft pathology or as a target for therapy.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Transplantology and Artificial Organs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15825/1995-1191-2023-2-148-157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Federation Clinical outcomes of solid organ transplantation depend on many factors. One of the main factors is the risk of post-transplant complications, which affect allograft and recipient survival. Multifactorial organ damage in post-transplant complications and the search for diagnostic and prognostic indicators of the condition have contributed to the study and selection of a wide range of proteomic and molecular genetic biomarkers, which have shown to be effective in solid organ transplantation. The use of biomarkers opens up additional possibilities for assessing the risk of complications and their early diagnosis. This potentially reduces the frequency of invasive diagnostic procedures. Transforming growth factor beta 1 (TGF-β1) regulates many biological processes, has anti-inflammatory and immunosuppressive effects, participates in immune response, and plays a key role in extracellular matrix (ECM) protein synthesis. ECM dysregulation leads to fibroblast hyperproliferation and increased collagen synthesis and, consequently, tissue fibrosis. The variability of the diagnostic and prognostic potential of TGF-β1 has been demonstrated in studies on recipients of various solid organs. The objective of this review is to analyze recent evidence on the role of TGF-β1 in the development of post-transplant complications and to assess its prospects as a marker of graft pathology or as a target for therapy.
转化生长因子β 1在实体器官移植中的诊断和治疗潜力:最新研究成果
实体器官移植的临床效果取决于许多因素。其中一个主要因素是移植后并发症的风险,它影响同种异体移植和受体的生存。移植后并发症中的多因素器官损伤,以及对该疾病诊断和预后指标的研究,促进了广泛的蛋白质组学和分子遗传生物标志物的研究和选择,这些标志物已被证明在实体器官移植中有效。生物标志物的使用为评估并发症的风险和早期诊断提供了更多的可能性。这可能会减少侵入性诊断程序的频率。转化生长因子β1 (TGF-β1)调节多种生物过程,具有抗炎和免疫抑制作用,参与免疫应答,在细胞外基质(extracellular matrix, ECM)蛋白合成中起关键作用。ECM失调导致成纤维细胞过度增殖和胶原合成增加,从而导致组织纤维化。TGF-β1的诊断和预后潜力的可变性已在各种实体器官受体的研究中得到证实。本综述的目的是分析TGF-β1在移植后并发症发生中的作用的最新证据,并评估其作为移植病理标志物或治疗靶点的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信